Agios Files for FDA OK of Mitapivat in PK Deficiency
June 21 2021 - 7:42AM
Dow Jones News
By Colin Kellaher
Agios Pharmaceuticals Inc. Monday said it filed for U.S. Food
and Drug Administration approval of mitapivat for the treatment of
adults with pyruvate kinase, or PK, deficiency.
The Cambridge, Mass., biopharmaceutical company said there are
currently no approved therapies for PK deficiency, a rare genetic
disorder characterized by the premature destruction of red blood
cells.
Agios said it is on track to file for European Union approval of
mitapivat in mid-2021.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 21, 2021 07:37 ET (11:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Sep 2023 to Sep 2024